Home


MGAE / MGA1-M
MYASTHENIA GRAVIS ADULT EVALUATION

Test Code MGAE / MGA1-M 
Test MYASTHENIA GRAVIS ADULT EVALUATION 
Methodology Radioimmunoassay (RIA) ACHRB, ACMOD, ACRGN, GAD65 and VGKC
Enzyme Immunoassay (EIA) - STMAB 
Description Useful for the initial evaluation of patients aged 20 or older with symptoms and signs of acquired myasthenia gravis (MG).
Bone marrow transplant recipients with suspected graft-versus-host disease, particularly if weakness has appeared.
Confirming that a recently acquired neurological disorder has an autoimmune basis (eg, MG).
Providing a quantitative baseline for future comparisons in monitoring a patient's clinical course and the response to immunomodulatory treatment.
Raising likelihood of neoplasia 
Specimen 3mL serum from a plain red top or serum gel tube. Patient should have no general anesthetic or muscle-relaxant drugs in the previous 24 hours 
Reference Values ACh RECEPTOR (MUSCLE) BINDING ANTIBODY
< or =0.02 nmol/L

ACh RECEPTOR (MUSCLE) MODULATING ANTIBODIES
0-20% (reported as __% loss of AChR)

STRIATIONAL (STRIATED MUSCLE) ANTIBODIES
<1:120 
Analytic Time 3-7 Days 
Day(s) Test Set Up Varies by Test Component 
CPT Code(s) 83519 x2  ACh receptor (muscle) binding antibody, ACh receptor (muscle) modulating antibodies AChR ganglionic neuronal antibody (if appropriate), Neuronal VGKC autoantibody (if appropriate)
83519 x2 (if appropriate)  AChR Ganglionic Neuronal Antibody (if appropriate), Neuronal VGKC Autoantibody (if Appropriate)
83520  Striational (striated muscle) antibodies
84182  CRMP-5-IgG Western blot (if appropriate)
86341  GAD65 antibody assay (if appropriate)